Rui Lixin, Drennan Amanda C, Ceribelli Michele, Zhu Fen, Wright George W, Huang Da Wei, Xiao Wenming, Li Yangguang, Grindle Kreg M, Lu Li, Hodson Daniel J, Shaffer Arthur L, Zhao Hong, Xu Weihong, Yang Yandan, Staudt Louis M
Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892;
Department of Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, WI 53705.
Proc Natl Acad Sci U S A. 2016 Nov 15;113(46):E7260-E7267. doi: 10.1073/pnas.1610970113. Epub 2016 Oct 31.
Janus kinases (JAKs) classically signal by activating STAT transcription factors but can also regulate gene expression by epigenetically phosphorylating histone H3 on tyrosine 41 (H3Y41-P). In diffuse large B-cell lymphomas (DLBCLs), JAK signaling is a feature of the activated B-cell (ABC) subtype and is triggered by autocrine production of IL-6 and IL-10. Whether this signaling involves STAT activation, epigenetic modification of chromatin, or both mechanisms is unknown. Here we use genetic and pharmacological inhibition to show that JAK1 signaling sustains the survival of ABC DLBCL cells. Whereas STAT3 contributed to the survival of ABC DLBCL cell lines, forced STAT3 activity could not protect these cells from death following JAK1 inhibition, suggesting epigenetic JAK1 action. JAK1 regulated the expression of nearly 3,000 genes in ABC DLBCL cells, and the chromatin surrounding many of these genes was modified by H3Y41-P marks that were diminished by JAK1 inhibition. These JAK1 epigenetic target genes encode important regulators of ABC DLBCL proliferation and survival, including IRF4, MYD88, and MYC. A small molecule JAK1 inhibitor cooperated with the BTK inhibitor ibrutinib in reducing IRF4 levels and acted synergistically to kill ABC DLBCL cells, suggesting that this combination should be evaluated in clinical trials.
Janus激酶(JAKs)传统上通过激活STAT转录因子来传递信号,但也可通过对酪氨酸41位点的组蛋白H3(H3Y41-P)进行表观遗传磷酸化来调节基因表达。在弥漫性大B细胞淋巴瘤(DLBCLs)中,JAK信号是活化B细胞(ABC)亚型的一个特征,由IL-6和IL-10的自分泌产生所触发。这种信号传导是涉及STAT激活、染色质的表观遗传修饰,还是这两种机制尚不清楚。在这里,我们使用基因和药物抑制来表明JAK1信号维持ABC DLBCL细胞的存活。虽然STAT3有助于ABC DLBCL细胞系的存活,但强制激活STAT3并不能保护这些细胞在JAK1抑制后免于死亡,这表明JAK1存在表观遗传作用。JAK1调节ABC DLBCL细胞中近3000个基因的表达,许多这些基因周围的染色质被H3Y41-P标记修饰,而这些标记在JAK1抑制后减少。这些JAK1表观遗传靶基因编码ABC DLBCL增殖和存活的重要调节因子,包括IRF4、MYD88和MYC。一种小分子JAK1抑制剂与BTK抑制剂依鲁替尼协同作用降低IRF4水平,并协同杀死ABC DLBCL细胞,这表明这种联合疗法应在临床试验中进行评估。